Protocol 331-13-009: An Exploratory, Multicenter, Randomized, Double-Blind, fMRI Study of Fixed-dose Brexpiprazole (OPC-34712) (2 and 4 mg/Day Tablets) in Adults With Schizophrenia With Impulsivity

Trial Profile

Protocol 331-13-009: An Exploratory, Multicenter, Randomized, Double-Blind, fMRI Study of Fixed-dose Brexpiprazole (OPC-34712) (2 and 4 mg/Day Tablets) in Adults With Schizophrenia With Impulsivity

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics; Registrational
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 11 Aug 2016 Status changed from recruiting to completed.
    • 29 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.
    • 29 Jan 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top